Our results demonstrated that US could spatiotemporally trigger production and secretion of IL-2 or sPD-1 in different syngeneic tumor mouse models, achieving robust therapeutic efficacy and minimizing toxic effects. This evidence concerns the gene HOXD13 and neoplasm.